About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Chicago | 533 Studies

Clinical Trials LymphomaChicago

Lymphoma Clinical Trials in Chicago

Find 533 clinical trials for lymphoma near Chicago, Illinois. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 441-460 of 533 trials

CompletedOfatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin LymphomaThis randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular…NCT01286272·La Jolla, California and 95 others

Lymphoma Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

Active not recruitingValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including…NCT04703192·Duarte, California and 59 others

CompletedFLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).NCT02448381·Birmingham, Alabama and 32 others

RecruitingA Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesThis study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111.NCT06528301·Duarte, California and 8 others

CompletedA Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorThis is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle…NCT03235544·Birmingham, Alabama and 102 others

CompletedLenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaThis Phase I/II trial studies the safety and effectiveness of lenalidomide with or without idelalisib.NCT01838434·Chicago, Illinois and 3 others

CompletedA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesThis is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of…NCT03310619·Duarte, California and 8 others

CompletedPRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily EnzastaurinThis clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily.NCT00332202·Anchorage, Alaska and 152 others

CompletedDepsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaBackground: NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy…NCT00007345·Scottsdale, Arizona and 12 others

CompletedComparison of Nutritional Supplements in Preventing Weight Loss in Patients With CancerRATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.NCT00053053·Birmingham, Alabama and 249 others

CompletedIPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaThis is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as…NCT03902184·Birmingham, Alabama and 52 others

CompletedStudy of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 TositumomabThe purpose of this study is to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who…NCT00062894·Bay Pines, Florida and 5 others

CompletedSafety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaAn open-label, multi-dose, single-arm, Phase 1 dose escalation study of XmAb®2513 was conducted to define the MTD or recommended dose(s) for further study, to determine safety and…NCT00606645·Chicago, Illinois and 3 others

CompletedSafety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to RituximabSUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent…NCT00139841·Birmingham, Alabama and 39 others

CompletedLenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaSubjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle.NCT00179673·Scottsdale, Arizona and 14 others

CompletedThalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaPhase II trial to study the effectiveness of thalidomide in treating patients who have relapsed or refractory low-grade non-Hodgkin's lymphoma.NCT00022581·Chicago, Illinois

CompletedA Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation…NCT01578499·Los Angeles, California and 40 others

CompletedChemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin LymphomaThis phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma.NCT01132807·Tucson, Arizona and 94 others

CompletedMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaThis phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or…NCT01231919·Birmingham, Alabama and 24 others

CompletedSafety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's LymphomaThis study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v.NCT00354926·Birmingham, Alabama and 10 others

PreviousPage 23 of 27Next

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia